Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.46 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MYC | P01106 | 1/20 | 0.48 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.47 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7029926 | 1.00 | ALDH1A1 (0.54) | ALDH1A1HPGDKDM4EMAPTTSHR | |
| Hydrochloric Acid SCHEMBL4369214 | 1.00 | ALDH1A1 (0.54) | ALDH1A1HPGDKDM4EMAPTTSHR | |
| SCHEMBL1558192 | 0.98 | ALDH1A1 (0.56) | ALDH1A1HPGDKDM4EMAPTTSHR | |
| SCHEMBL6099 | 0.98 | ALDH1A1 (0.56) | ALDH1A1HPGDKDM4EMAPTTSHR | |
| Hydroxyamine SCHEMBL8105651 | 0.95 | ALDH1A1 (0.54) | ALDH1A1HPGDKDM4EMAPTTSHR | |
| SCHEMBL3870822 | 0.95 | ALDH1A1 (0.54) | ALDH1A1HPGDKDM4EMAPTTSHR | |
| SCHEMBL28394928 | 0.95 | ALDH1A1 (0.54) | ALDH1A1HPGDKDM4EMAPTTSHR | |
| Methylamine SCHEMBL28283262 | 0.95 | ALDH1A1 (0.54) | ALDH1A1HPGDKDM4EMAPTTSHR | |
| Ammonia Solution, Strong SCHEMBL28231571 | 0.95 | ALDH1A1 (0.54) | ALDH1A1HPGDKDM4EMAPTTSHR | |
| Water SCHEMBL27485902 | 0.95 | ALDH1A1 (0.54) | ALDH1A1HPGDKDM4EMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4175949-A1 | METHODS AND COMPOSITIONS FOR TARGETING TREGS USING CCR8 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2023-05-10 | — | — | EP | claimed |
| CN-115989223-A | Methods and compositions for targeting Tregs using CCR8 inhibitors | 南京艾美斐生物医药科技有限公司 | 2023-04-18 | — | — | CN | claimed |
| WO-2017217895-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTICOAGULANT N-(5-CHLOROPYRIDINE-2-YL)-2-({4-[ETHANIMIDOIL(METHYL)AMINO]BENZOYL}AMINO)-5-METHYLBENZAMIDE | "PHARMADIALL" LTD (RU) | 2017-12-21 | — | — | WO | claimed |
| EP-1597251-A2 | PYRIMIDINE COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-11-23 | — | — | EP | claimed |
| WO-2004074244-A2 | PYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-09-02 | — | — | WO | claimed |
| JP-9124600-A | — | — | None | — | — | JP | disclosed |
| US-12637492-B2 | Peptide inhibitors of focal adhesion kinase activity and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-05-26 | — | — | US | disclosed |
| US-12528815-B2 | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer | NXERA PHARMA UK LIMITED (GB) | 2026-01-20 | — | — | US | disclosed |
| US-12521386-B2 | Small molecule inhibitors of the androgen receptor activity and/or expression and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-01-13 | — | — | US | disclosed |
| US-12509468-B2 | Quindoline compounds and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250189527-A1 | COMPOSITIONS AND METHODS FOR DETECTING, PREDICTING RISK OF DEVELOPING, AND TREATING LEPTOMENINGEAL DISEASE | DUKE UNIVERSITY | 2025-06-12 | — | — | US | disclosed |
| CN-120129464-A | Flavonoid compound and application thereof | 弗门尼舍有限公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20060270689-A1 | Novel Fused Heterocycles and Uses Thereof | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| US-20060063751-A1 | Novel fused heterocycles and uses thereof | ASTRAZENECA AB (SE) | 2006-03-23 | — | — | US | disclosed |
| US-20060041128-A1 | Selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
| US-20060041129-A1 | Enantiomers of selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
| EP-1597251-A2 | PYRIMIDINE COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004074244-A2 | PYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2002047726-A2 | PHARMACEUTICAL COMPOSITION CONTAINING AN ACTIVE WITH A HEMOLYTIC ACTION AND A SURFACTANT | JAPAN TOBACCO INC. (JP) | 2002-06-20 | — | — | WO | disclosed |
| JP-H09124600-A | NEW PIPERIDINE DERIVATIVE, METHOD FOR OBTAINING THE SAME, AND PHARMACOLOGICAL, COMPOSITION CONTAINING THE SAME | SANOFI SA | 1997-05-13 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063751-A1 | Novel fused heterocycles and uses thereof | RB1, CDK19, PRMT9 | MAOA 3468/4885MAOB 1772/4885ALDH1A1 672/4885 |
| US-12509468-B2 | Quindoline compounds and uses thereof | TPD52L2, BRDT, RECQL | MAOA 4390/4885MAOB 3819/4885ALDH1A1 1662/4885 |
| US-12528815-B2 | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer | ADORA1, ADORA3, OPRL1 | MAOA 483/4885MAOB 597/4885ALDH1A1 692/4885 |
| US-20060041128-A1 | Selected fused heterocyclics and uses thereof | SDHA, CYP11B2, NQO1 | MAOA 1003/4885MAOB 414/4885ALDH1A1 293/4885 |
| US-12637492-B2 | Peptide inhibitors of focal adhesion kinase activity and uses thereof | PTK2, ILK, FPR2 | MAOA 4830/4885MAOB 4828/4885ALDH1A1 4794/4885 |
| US-20060041129-A1 | Enantiomers of selected fused heterocyclics and uses thereof | CYP11B2, HCCS, CYP11B1 | MAOA 1193/4885MAOB 492/4885ALDH1A1 214/4885 |
| US-20060270689-A1 | Novel Fused Heterocycles and Uses Thereof | BRCA1, CYP1B1, CCNI | MAOA 3375/4885MAOB 1475/4885ALDH1A1 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.